Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001883850-22-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-04-04 | 2022-03-31 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | S - Sale | $710.01 | -2,886 | 18.3K | -14% | -$2.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | S | D | 2,886 | $710.01 | 18,292 | I By Trust | — | — | (F2) Represents volume-weighted average price of sales of 2,886 shares of Company stock on March 31, 2022 at prices ranging from $710.00 to $710.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 31, 2022 at each separate price. |